THE PEOPLE BEHIND THE PUBLICATIONS
Public profiles and publication affiliations help put the research in context. Inclusion here is a record of scholarly work, not a partnership, endorsement or hospital ranking.
Research lead / corresponding author
A corresponding author of the foundational PRaG phase II paper and an investigator in subsequent PRaG programs. His university profile describes the development of PRaG beginning in 2019.
Source profile / publication ↗Research author
An author of the foundational PRaG report and the first listed author of the 2025 ASCO PRaG 2.0 abstract.
Source profile / publication ↗Research author
First author of the 2022 PRaG phase II report and the 2024 PRaG 5.0 study protocol.
Source profile / publication ↗AFFILIATIONS, VERIFIED AT SOURCE
Suzhou
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Safety and efficacy of PRaG therapy in elderly cancer patients ↗Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol) ↗Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol) ↗All linked publications →Nanchong
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report ↗All linked publications →Shanghai
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial ↗All linked publications →Guiyang
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Case Report: Multidisciplinary management of primary inferior vena cava leiomyosarcoma: a comprehensive case study ↗All linked publications →Nanjing
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial ↗PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review ↗All linked publications →Wuxi
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Long-term survival in a patient with leptomeningeal metastases from non-small cell lung cancer treated with stereotactic radiotherapy (SRT), programmed cell death protein 1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF): a case report ↗All linked publications →Ningxia
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Safety and efficacy of PRaG therapy in elderly cancer patients ↗All linked publications →Wuhan
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review ↗All linked publications →Shanghai / Wuxi
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Long-term survival in a patient with leptomeningeal metastases from non-small cell lung cancer treated with stereotactic radiotherapy (SRT), programmed cell death protein 1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF): a case report ↗All linked publications →Luzhou
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer ↗All linked publications →Yixing
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report ↗All linked publications →Bengbu
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Efficacy and immune characteristics of a PRaG-based regimen in advanced refractory solid tumors ↗All linked publications →Nanning
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer ↗All linked publications →Xi’an
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
CXCR5+ monocyte emigration impairs the radiation-induced antitumor immune response ↗Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies ↗All linked publications →Suining
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer ↗All linked publications →Chengdu
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer ↗All linked publications →Xi’an
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report ↗All linked publications →Xuzhou
Listed through authorship affiliations in the cited publication. Inclusion does not imply partnership with this website.
Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial ↗PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review ↗All linked publications →